Clinical Trial: A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors

U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07554196) titled 'A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors' on April 10.

Brief Summary: The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.

Study Start Date: Jan. 19, 2022

Study Type: INTERVENTIONAL

Condition: Solid Tumor

Intervention: DRUG: HH-101 (0.3 mg/kg)

Participants received 0.3 mg/kg HH-101 as an intravenous (IV) infusion on day (D)1 and D21 of each 21-day cycle every 3 weeks (Q3W).

DRUG: HH-101 (1 mg/kg )

Participants received 1 mg/k...